ArcticZymes launches dsDNase Triton FREE

ArcticZymes AS is pleased to announce the launch of dsDNase Triton FREE. This launch is a continuing step towards maintaining a completely EU REACH compliant product portfolio after Triton X-100 becomes subject to authorisation in January 2021 and facilitate a smooth transition for our existing dsDNase customers. dsDNase Triton FREE is available for shipping. You can request a quote by contacting …

ASGCT Annual Meeting in Boston

ArcticZymes will be exhibiting at The American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in Boston, May 12th to May 15th. Learn more ›

ArcticZymes presents joint poster with the Cell and Gene Therapy Catapult

SAN HQ developed by ArcticZymes has quickly found its place as a valuable tool in manufacture of gene-delivery vehicles (viral vectors) applicable in gene therapy. In cooperation with the Cell and Gene Therapy Catapult, a centre of excellence in innovation, with the core purpose of building a world-leading cell and gene therapy sector in the UK, ArcticZymes presented a scientific …

ArcticZymes expands dsDNase product portfolio

ArcticZymes AS is pleased to announce the launch of dsDNase Glycerol-free Triton FREE. This launch is a continuing step towards maintaining a completely EU REACH compliant product portfolio after Triton X-100 becomes subject to authorisation in January 2021 and facilitate a smooth transition for our existing dsDNase customers. dsDNase Glycerol-free Triton FREE is available for shipping. You can request a …